Effects of raloxifene administration on serum levels of insulin-like growth factor-1 and insulin-like growth factor-binding protein 3 levels: A systematic review and meta-analysis of randomized controlled trials

• Published in: Growth hormone & IGF research Vol. 60-61; p. 101421
• Main Authors: Sun, Yan, Xiong, Ying, Meng, Yong Liang, Santos, Heitor O., Athayde, Felipe L., de Souza, Ivan G.O., Yang, Ling
• Format: Journal Article
• Language: English
• Published: Scotland Elsevier Ltd 01-10-2021
• Subjects: Biomarkers - blood; Breast Neoplasms - blood; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - pathology; Female; Humans; IGF-1; IGFBP-3; Insulin-Like Growth Factor Binding Protein 3 - blood; Insulin-Like Growth Factor I - analysis; Postmenopause; Prognosis; Raloxifene; Raloxifene Hydrochloride - administration & dosage; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators - administration & dosage; IGFBP-3; Raloxifene; IGF-1
• ISSN: 1096-6374; 1532-2238
• DOI: 10.1016/j.ghir.2021.101421

To ascertain the clinical magnitude of raloxifene administration on insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-binding protein 3 (IGFBP-3) levels.
A systematic comprehensive search was performed without language limitation up to 14 December 2020. We included only trials that assessed the effect of raloxifene on IGF-1 and IGFBP-3 in adults. Meta-analysis was performed using the Stata software (Stata Corp. College Station, Texas, USA).
Seven arms were included, encompassing postmenopausal women with type 2 diabetes mellitus, postmenopausal women with breast cancer, healthy postmenopausal women, and healthy elderly men. Raloxifene therapy significantly reduced IGF-1 levels (WMD: −2.92 nmol/L, 95% CI: −3.49, −2.35, p < 0.001) compared to placebo. Raloxifene dosage ˃60 mg/day (WMD: −3.29 ng/mL, 95% CI: −3.50 to −3.08, I2 = 0.0%) decreased IGF-1 levels more than 60 mg/day (WMD: −2.29 ng/mL, 95% CI: −2.90 to −1.69, I2 = 16%). Moreover, intervention duration ˃26 weeks (WMD: −3.48 ng/mL, 95% CI: −5.26 to −1.69, I2 = 0.0%) reduced IGF-1 levels more than ˂26 weeks (WMD: −2.55 ng/mL, 95% CI: −3.31 to −1.79, I2 = 92%). In contrast, overall results from the random-effects model did not suggest a significant change in IGFBP-3 levels upon raloxifene therapy.
Raloxifene therapy significantly reduced serum levels of IGF-1 levels but without changes in IGFPB-3 levels.
•Raloxifene therapy significantly reduced serum levels of IGF-1.•In contrast, raloxifene therapy did not change IGFPB-3 levels.•Raloxifene dosage ˃60 mg/day decreased IGF-1 levels more than 60 mg/day.